CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Recruiting · NCT06479356 · Registry updated 2024-08-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 2 | 2024-08-21 | NCT06479356 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Ming Ju Biotechnology Co., Ltd. | 7 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Cancer Hospital | Tianjin | China | 14 |